Deciphera Pharmaceuticals
Deciphera Pharmaceuticals is developing novel drug candidates to improve the lives of cancer patients by targeting key mechanisms of tumor and drug resistance that limit the effectiveness of existing cancer therapies. Enabled by our proprietary kinase switch control inhibitor platform, our drug candidates are being designed to stop cancers from growing and spreading by inhibiting mutant forms or over expression of a family of enzymes called kinases. We have built a diverse pipeline of wholly-owned, orally administered drug candidates, including 3 clinical-stage and 2 research-stage programs.